Article Data

  • Views 269
  • Dowloads 144

Original Research

Open Access

Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinumrefractory/resistant epithelial ovarian cancer

  • H. Nomura1
  • H. Tsuda1,*,
  • F. Kataoka1
  • T. Chiyoda1
  • W. Yamagami1
  • E. Tominaga1
  • N. Susumu1
  • D. Aoki1

1Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan

DOI: 10.12892/ejgo20120186 Vol.33,Issue 1,January 2012 pp.86-89

Published: 10 January 2012

*Corresponding Author(s): H. Tsuda E-mail: htsud@sc.itc.keio.ac.jp

Abstract

Purpose: The standard regimen for platinum-resistant/refractory recurrent epithelial ovarian cancer (EOC) remains to be determined. In this study, we retrospectively compared the effect of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in the treatment of platinum-resistant recurrent EOC. Methods: Thirty patients who received salvage chemotherapy with CPT-11 or PLD were included in the study. CPT-11 (100 mg/m(2)) was administered intravenously on days I, 8 and 15 every four weeks. PLD (50 mg/m2) was administered on day 1 every four weeks. Treatment was repeated, provided that no disease progression or intolerable toxicity occurred. Results: Response rate in the CPT-11 group and PLD group showed no difference at 26.7% (p = 0.66) in both, while non-PD rate was 73.3% vs 33.3% (p < 0.05). respectively. Progression-free survival after CPT-11 treatment and PLD treatment was 28.4 weeks and 16.8 weeks (p = 0.07), respectively. Hand-foot syndrome and mucositis were more common in the PLD group than in the CPT-II group (p < 0.05). Conclusions: The results indicate that CPT-11 is a promising drug for the treatment of platinum-resistant recurrent EOC.

Keywords

Ovarian cancer; Recurrence; Platinum-resistant; Irinotecan; Liposomal doxorubicin

Cite and Share

H. Nomura,H. Tsuda,F. Kataoka,T. Chiyoda,W. Yamagami,E. Tominaga,N. Susumu,D. Aoki. Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinumrefractory/resistant epithelial ovarian cancer. European Journal of Gynaecological Oncology. 2012. 33(1);86-89.

References

[1] Japan Society of Gynecologic Oncology. Ovarian Cancer Treatment Guidelines 2007. Tokyo, Japan, Kanehara & Co., Ltd; 2007.

[2] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y. et al.: “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer”. N. Engl. J. Med., 1996, 334, 1.

[3] The National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (Version 2. 2010). Database online, 2010.

[4] Matsumoto K., Katsumata N., Yamanaka Y., Yonemori K., Kohno T., Shimizu C et al.: “The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer”. Gynecol. Oncol., 2006, 100, 412.

[5] Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A. et al.: “Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer”. J. Clin. Oncol., 2008, 26, 890.

[6] Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J.: “Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan”. J Clin Oncol. 2001, 19, 3312.

[7] Mutch D.G., Orlando M., Goss T., Teneriello M.G., Gordon A.N., McMeekin S.D. et al.: “Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer”. J. Clin. Oncol., 2007, 25, 2811.

[8] ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I. et al.: “Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer”. J. Clin. Oncol., 1997, 15, 2183.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top